Online inquiry

IVTScrip™ mRNA-Anti-ALB&IL6R, 20A11-9mer-ALB11(Cap 0, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ348MR)

This product GTTS-WQ348MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets ALB&IL6R gene. The antibody can be applied in Inflammatory conditions, Systemic lupus erythematosus (SLE) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_000477.7; NM_002190.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 213; 3570
UniProt ID P02768; P08887
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ALB&IL6R, 20A11-9mer-ALB11(Cap 0, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ348MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ780MR IVTScrip™ mRNA-Anti-AXL, Ab-2(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA Ab-2
GTTS-WQ2599MR IVTScrip™ mRNA-Anti-MPL, AMG 531(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA AMG 531
GTTS-WQ14376MR IVTScrip™ mRNA-Anti-TNF, r-hTBP-1(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA r-hTBP-1
GTTS-WQ8274MR IVTScrip™ mRNA-Anti-GHR, HM10560A(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA HM10560A
GTTS-WQ10750MR IVTScrip™ mRNA-Anti-ADAMTSL5&ALB, M-6495(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA M-6495
GTTS-WQ517MR IVTScrip™ mRNA-Anti-CD40, 4D11(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA 4D11
GTTS-WQ12141MR IVTScrip™ mRNA-Anti-CD248, MORAb-004(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MORAb-004
GTTS-WQ11441MR IVTScrip™ mRNA-Anti-NT5E, MEDI-9447(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA MEDI-9447
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW